Roche Wakes Up to New Competition as FDA Approves Amneal’s Avastin Biosimilar

Amneal Pharmaceuticals received the green light from the U.S. Food and Drug Administration for bevacizumab-maly, a biosimilar to Genentech (Roche)’s Avastin. The biosimilar approval marks the second for Amneal this year.